Maurer C A, Graber H U, Friess H, Beyermann B, Willi D, Netzer P, Zimmermann A, Büchler M W
Department of Visceral and Transplantation Surgery, University of Bern, Inselspital, Switzerland.
Surgery. 1999 Nov;126(5):869-80.
The expression of the KAI1 gene and its gene product were studied in metastatic and non-metastatic human colorectal cancer to evaluate its role in the metastatic process.
KAI1 mRNA and protein expression was examined in 36 primary colorectal carcinomas and 6 liver metastasis using Northern blot and Western blot analyses. Forty-six normal colonic tissue samples served as controls. The exact site of KAI1 expression was analyzed by in situ hybridization and by immunohistochemistry in primary tumors, in the corresponding normal tissues, in lymph node metastases and liver metastases.
Densitometric analysis of Northern blots revealed overexpression of KAI1 mRNA in 87% of colonic cancer tissues in comparison with the corresponding normal colonic tissues. This increase was 9.1-fold in median (P < .001). KAI1 mRNA expression was strongly dependent on tumor stage. Colorectal cancer at stages II and III revealed significantly higher KAI1 mRNA levels than stage IV tumors (P < .03 and P < .015, respectively) or normal controls. In addition, liver metastases showed reduced KAI1 mRNA expression when compared with their corresponding primary tumor. In situ hybridization confirmed the stage-dependent expression results obtained by Northern blots, in which the KAI1 mRNA signal was exhibited almost exclusively in the epithelial cells. Lymph node and liver metastases were largely devoid of KAI1 mRNA. Western blot analysis showed a highly significant increase of KAI1 protein level in stage II cancers in comparison with the normal colon (P < .001) but also in comparison with the more advanced tumor stages III and IV (P < .03) and P < .02, respectively), when metastases were already present. In accordance, KAI1 immunostaining decreased successively with the advance of the tumor stage and was absent in lymph node and liver metastases.
These data demonstrate that the KAI1 mRNA expression and the KAI1 protein level increase in an earlier tumor stage of colorectal cancer, decrease in advanced stages, and are lost in metastases. The loss of KAI1 might favor the ability of colorectal cancer cells to metastasize.
研究KAI1基因及其基因产物在转移性和非转移性人类结直肠癌中的表达,以评估其在转移过程中的作用。
采用Northern印迹和Western印迹分析,检测36例原发性结直肠癌和6例肝转移灶中KAI1 mRNA和蛋白的表达。46例正常结肠组织样本作为对照。通过原位杂交和免疫组织化学分析原发性肿瘤、相应正常组织、淋巴结转移灶和肝转移灶中KAI1表达的确切部位。
Northern印迹的光密度分析显示,与相应正常结肠组织相比,87%的结肠癌组织中KAI1 mRNA过表达。中位数增加9.1倍(P <.001)。KAI1 mRNA表达强烈依赖于肿瘤分期。II期和III期结直肠癌的KAI1 mRNA水平显著高于IV期肿瘤(分别为P <.03和P <.015)或正常对照。此外,与相应的原发性肿瘤相比,肝转移灶的KAI1 mRNA表达降低。原位杂交证实了Northern印迹获得的分期依赖性表达结果,其中KAI1 mRNA信号几乎仅在上皮细胞中显示。淋巴结和肝转移灶中大多没有KAI1 mRNA。Western印迹分析显示,与正常结肠相比,II期癌症中KAI1蛋白水平显著升高(P <.001),但与更晚期的III期和IV期肿瘤相比也显著升高(分别为P <.03和P <.02),此时已有转移。相应地,KAI1免疫染色随着肿瘤分期的进展而逐渐降低,在淋巴结和肝转移灶中不存在。
这些数据表明,KAI1 mRNA表达和KAI1蛋白水平在结直肠癌的早期肿瘤阶段升高,在晚期降低,并在转移灶中消失。KAI1的缺失可能有利于结直肠癌细胞的转移能力。